Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes

Pospisilova,Jana; Vit,Ondrej; Lorkova,Lucie; Klanova,Magdalena; Zivny,Jan; Klener,Pavel; Petrak,Jiri

doi:10.3892/ijmm.2013.1302

Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes

Authors:
- Jana Pospisilova
- Ondrej Vit
- Lucie Lorkova
- Magdalena Klanova
- Jan Zivny
- Pavel Klener
- Jiri Petrak
View Affiliations

Affiliations: Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 128 53 Prague, Czech Republic
Published online on: March 13, 2013 https://doi.org/10.3892/ijmm.2013.1302
Pages: 1273-1279

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mantle cell lymphoma (MCL) is a rare aggressive type of B-cell non-Hodgkin's lymphoma. Response to chemotherapy tends to be short and virtually all patients sooner or later relapse. The prognosis of relapsed patients is extremely poor. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered one of the novel experimental molecules with strong antitumor effects. TRAIL triggers extrinsic apoptotis in tumor cells by binding to TRAIL ‘death receptors’ on the cell surface. Recombinant TRAIL has shown promising pro-apoptotic effects in a variety of malignancies including lymphoma. However, as with other drugs, lymphoma cells can develop resistance to TRAIL. Therefore, the aim of this study was to identify the molecular mechanisms responsible for, and associated with TRAIL resistance in MCL cells. If identified, these features may be used as molecular targets for the effective elimination of TRAIL-resistant lymphoma cells. From an established TRAIL-sensitive mantle cell lymphoma cell line (HBL-2) we derived a TRAIL-resistant HBL-2/R subclone. By TRAIL receptor analysis and differential proteomic analysis of HBL-2 and HBL-2/R cells we revealed a marked downregulation of all TRAIL receptors and, among others, the decreased expression of 3 key enzymes of purine nucleotide metabolism, namely purine nucleoside phosphorylase, adenine phosphoribosyltransferase and inosine-5'-monophosphate dehydrogenase 2, in the resistant HBL-2/R cells. The downregulation of the 3 key enzymes of purine metabolism can have profound effects on nucleotide homeostasis in TRAIL-resistant lymphoma cells and can render such cells vulnerable to any further disruption of purine nucleotide metabolism. This pathway represents a ‘weakness’ of the TRAIL-resistant MCL cells and has potential as a therapeutic target for the selective elimination of such cells.

View Figures

View References

1	Sant M, Allemani C, Tereanu C, et al: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 116:3724–3734. 2010. View Article : Google Scholar : PubMed/NCBI
2	Perez-Galan P, Dreyling M and Wiestner A: Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 117:26–38. 2011. View Article : Google Scholar : PubMed/NCBI
3	Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC and Croce CM: Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science. 224:1403–1406. 1984. View Article : Google Scholar : PubMed/NCBI
4	Williams ME, Swerdlow SH, Rosenberg CL and Arnold A: Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res. 52:5541S–5544S. 1992.PubMed/NCBI
5	Humala K and Younes A: Current and emerging new treatment strategies for mantle cell lymphoma. Leuk Lymphoma. Feb 19–2013.(Epub ahead of print).
6	Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
7	Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
8	Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
9	Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:818–821. 1997. View Article : Google Scholar : PubMed/NCBI
10	Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2:420–430. 2002. View Article : Google Scholar : PubMed/NCBI
11	Castro Alves C, Terziyska N, Grunert M, et al: Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood. 119:4224–4227. 2012.PubMed/NCBI
12	Peter ME and Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26–35. 2003. View Article : Google Scholar : PubMed/NCBI
13	Spierings DC: Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 52:821–831. 2004. View Article : Google Scholar : PubMed/NCBI
14	Petrak J, Toman O, Simonova T, et al: Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts. Proteomics. 9:5006–5015. 2009. View Article : Google Scholar : PubMed/NCBI
15	Molinsky J, Klanova M, Koc M, et al: Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Leuk Lymphoma. 54:372–380. 2013. View Article : Google Scholar
16	Klener P, Leahomschi S, Molinsky J, et al: TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine. Blood Cells Mol Dis. 42:77–84. 2009. View Article : Google Scholar : PubMed/NCBI
17	Leahomschi S, Molinsky J, Klanova M, et al: Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL). Neoplasma. 60:223–231. 2013. View Article : Google Scholar
18	Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E and Bhalla K: Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood. 96:3900–3906. 2000.PubMed/NCBI
19	Plasilova M, Zivny J, Jelinek J, et al: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 16:67–73. 2002. View Article : Google Scholar : PubMed/NCBI
20	Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
21	Di Pietro R and Zauli G: Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol. 201:331–340. 2004.
22	Kelley SK, Harris LA, Xie D, et al: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 299:31–38. 2001.
23	Lawrence D, Shahrokh Z, Marsters S, et al: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 7:383–385. 2001. View Article : Google Scholar : PubMed/NCBI
24	Roth W, Isenmann S, Naumann U, et al: Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun. 265:479–483. 1999. View Article : Google Scholar : PubMed/NCBI
25	Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999. View Article : Google Scholar : PubMed/NCBI
26	Hylander BL, Pitoniak R, Penetrante RB, et al: The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med. 3:222005. View Article : Google Scholar : PubMed/NCBI
27	Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A and Ford HL: On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 14–May;2012.(Epub ahead of print). View Article : Google Scholar : 1642012.PubMed/NCBI
28	Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
29	Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F and Mijatovic S: Resistance to TRAIL and how to surmount it. Immunol Res. 52:157–168. 2012. View Article : Google Scholar : PubMed/NCBI
30	Scavennec J, Maraninchi D, Gastaut JA, Carcassonne Y and Cailla HL: Purine and pyrimidine ribonucleoside monophosphate patterns of peripheral blood and bone marrow cells in human acute leukemias. Cancer Res. 42:1326–1330. 1982.PubMed/NCBI
31	Natsumeda Y, Prajda N, Donohue JP, Glover JL and Weber G: Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues. Cancer Res. 44:2475–2479. 1984.PubMed/NCBI
32	Bollee G, Harambat J, Bensman A, Knebelmann B, Daudon M and Ceballos-Picot I: Adenine phosphoribosyltransferase deficiency. Clin J Am Soc Nephrol. 7:1521–1527. 2012. View Article : Google Scholar
33	Bantia S, Miller PJ, Parker CD, et al: Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 1:1199–1210. 2001. View Article : Google Scholar : PubMed/NCBI
34	Bantia S, Montgomery JA, Johnson HG and Walsh GM: In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology. 35:53–63. 1996. View Article : Google Scholar : PubMed/NCBI
35	Galmarini CM, Popowycz F and Joseph B: Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Curr Med Chem. 15:1072–1082. 2008. View Article : Google Scholar : PubMed/NCBI
36	Allison AC and Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 47:85–118. 2000. View Article : Google Scholar : PubMed/NCBI
37	Hedstrom L: IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 109:2903–2928. 2009. View Article : Google Scholar : PubMed/NCBI
38	Fairbanks LD, Ruckemann K, Qiu Y, et al: Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J. 342:143–152. 1999. View Article : Google Scholar
39	Allison AC and Eugui EM: The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol. 14:353–380. 1993. View Article : Google Scholar : PubMed/NCBI
40	Zhou S, Liu R, Baroudy BM, Malcolm BA and Reyes GR: The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 310:333–342. 2003. View Article : Google Scholar : PubMed/NCBI
41	Gandhi V, Kilpatrick JM, Plunkett W, et al: A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 106:4253–4260. 2005. View Article : Google Scholar
42	Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK and Schramm VL: One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 37:8615–8621. 1998. View Article : Google Scholar : PubMed/NCBI